PrEP | Pre-Exposure Prophylaxis Provider Reference

PrEP Options	Indicated For:	Administration:	Considerations:
Daily Oral Truvada® (F/TDF) 200mg/300mg	Individuals ≥35kg	l pill once daily	Generics available Requires renal monitoring. May cause decreased bone mineral density and kidney effects.
Daily Oral Descovy® (F/TAF) 200mg/25mg	Cisgender men and transgender women ≥35kg	l pill once daily	No generic alternative Only approved for use in cisgender men and transgender women. May cause weight gain.
Injectable Cabotegravir 600mg	Individuals ≥35kg	Optional 4-week oral dosing lead-in OR initial injection followed by second injection at 30 days. Alternate month administration thereafter.	No generic alternative Requires in-person visits for injection administration. May cause injection site reaction.
Off-Label, On-Demand Truvada® (F/TDF) 200mg/300mg	Men who have sex with men ≥35kg	2 pills 2-24 hrs prior to sex I pill 24 hours after initial dose I pill 48 hours after initial dose	Generics available Best for MSM who have sex infrequently or can anticipate (or delay) sexual activity to accommodate the complete dosing schedule. Considered off-label; may not be covered by insurance.

Oral PrEP Regimen Management

Truvada® (F/TDF) is approved for use in all persons weighing at least 35kg.

Descovy® (F/TAF) is approved for use in all cisgender men and transgender women weighing at least 35kg.

Oral PrEP should be prescribed in 90-day increments and refilled only when a patient has a documented negative HIV monitoring test.

Test	Initiation	Every 3 Months	Every 6 Months	Every 12 Months	Discontinuation
HIV Test	Test & screen for signs/symptoms of acute HIV	HIV-I RNA			HIV-I RNA & screen for signs/symptoms of acute HIV
Serum Creatinine Clearance	\checkmark		If age 50 or older or when eCrCl <90 ml/ min at initiation	If age <50 and eCrCl >89 ml/min at initiation	\checkmark
Syphilis	~	MSM/TGW	~		MSM/TGW
Gonorrhea/Chlamydia	~	MSM/TGW	~		MSM/TGW
Lipid Panel	F/TAF Only			F/TAF Only	
Hepatitis B	~				
Hepatitis C	MSM, TGW, PWID			MSM, TGW, PWID	

Long Acting Injectable PrEP Regimen Management

600mg Cabotegravir injected into gluteal muscle every 2 months. 30mg daily oral cabotegravir is optional for a 4-week lead-in prior to injections.

Test	Initiation	I Month	Every 2 Months	Every 4 Months	Every 6 Months	Every 12 Months	Discontinuation
HIV-I RNA	\checkmark	~	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Syphilis	\checkmark			MSM/TGW	Heterosexual	\checkmark	MSM/TGW
Gonorrhea	\checkmark			MSM/TGW	Heterosexual	\checkmark	MSM/TGW
Chlamydia	\checkmark			MSM/TGW	Heterosexual	Heterosexual	MSM/TGW

Checkmark (✓) = required for all users.
Population-specific considerations denoted in text.
MSM = Men who have sex with men
TGW = Transgender women
PWID = Person who injects drugs

Heterosexual = Heterosexually active men & women Access more information at: prepiowa.org/provider For further training and technical assistance, contact: HIV and Hepatitis Prevention Program Bureau of HIV, STI, and Hepatitis Division of Public Health, Iowa HHS hivhcvprevention@idph.iowa.gov

Public Health

Information in this resource is derived from the Centers for Disease Control and Prevention's 2021 Clinical Practice Guidelines, which can be accessed at prepiowa.org/provider.